ArticleEClinicalMedicine2023

SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial.

Ramses Vega et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.